Results 171 to 180 of about 27,004 (255)

Diagnostic Significance of Selected Plasma MicroRNAs in Myelodysplastic Syndromes. [PDF]

Int J Mol Sci
Atanasova S, Chervenkov T, Teneva M, Dimitrova S, Micheva I.   +4 more
europepmc   +1 more source

Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT‐SAAWP RACE Study

American Journal of Hematology, Volume 101, Issue 10, Page 2520-2532, October 2026.
ABSTRACT The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2‐year analysis of this prospective randomized phase III study.
Antonio M. Risitano, Simona Iacobelli, Austin Kulasekararaj, Marleen van Os, Sofie R. Terwel, Joe Tuffnell, Brian Piepenbroek, Morag Griffin, Constantijn J. M. Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Juan Carlos Vallejo, Beatrice Drexler, Jean‐Baptiste Mear, Roochi Trikha, Shreyans Gandhi, Anna Maria Raiola, L. G. M. Daenen, Marco R. de Groot, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H. Russell, Louis Terriou, Anna Paola Iori, Walter Barberi, Anna Sureda, Isabel Sánchez‐Ortega, Blanca Xicoy, Isidro Jarque, James Cavenagh, Flore Sicre de Fontbrune, Camilla Frieri, Talha Munir, Jennifer M. L. Tjon, Suzanne Tavitian, Aline Praire, Laurence Clement, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Serena Marotta, Fabiana Cacace, Marica Laurino, Jakob R. Passweg, Gérard Socié, Ghulam J. Mufti, Carlo Dufour, Régis Peffault de Latour, Severe Aplastic Anaemia Working Party of the EBMT   +52 more
wiley   +1 more source

Is the combination of Myelodysplastic syndromes and pulmonary fibrosis accidental or inevitable? [PDF]

Multidiscip Respir Med
He Y, Li Y, Wang Y, Zhang J, Chen H, Chen J, Zhao Y.   +6 more
europepmc   +1 more source

The Homozygous p.(Arg215Ter) Variant in XRCC2 Is Associated With Atypical Fanconi Anemia Without Major Hematological Abnormalities in Childhood

American Journal of Medical Genetics Part A, Volume 200, Issue 10, Page 2331-2337, October 2026.
ABSTRACT Fanconi Anemia (FA) is the most frequent inherited bone marrow failure syndrome. A role for the XRCC2 gene in FA was suspected in 2012 and confirmed in 2016, but only two affected individuals have been described thus far, and no long‐term follow‐up is available.
Sabina Cenciarelli, Giulia Bruna Marchetti, Maria Iascone, Maria Grazia Patricelli, Sara Giangiobbe, Gabriella Cinzia Pozzobon, Miriam Nella Savini, Fabio Giglio, Alessandro Aiuti, Paola Carrera, Francesca Ferrua, Angela Peron   +11 more
wiley   +1 more source

Reframing-renaming(?)-myelodysplastic syndromes/neoplasms and clonal hematopoiesis of indeterminate potential. [PDF]

Leukemia
Lee NC, Miao R, Young NS.
europepmc   +1 more source

The Impact of SF3B1 Mutations on the Tumor Microenvironment and Response to Immunotherapy

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Cancer genomes shape the immune landscape within the tumor microenvironment (TME), thereby influencing host antitumor immunity. Identifying somatic mutations that modulate the TME is critical for selecting patients most likely to benefit from immunotherapy.
Kyung‐Jin Cho, Byungho Lim
wiley   +1 more source

Novel Approaches to the Management of Myelodysplastic Syndromes: The Roles of Artificial Intelligence and Oxidative Stress Biomarkers. [PDF]

Hematol Rep
Tsamesidis I, Drillis G, Varlamis S, Smaragdaki N, Klonizakis P, Dimou M, Liapis K, Vrahiolias G, Andreadou E, Mitka S, Chatzidimitriou M, Kotsianidis I, Skepastianos P, Kriebardis AG, Pessach I.   +14 more
europepmc   +1 more source

Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower‐risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo‐controlled trial

Cancer, Volume 132, Issue 19, 1 October 2026.
Abstract Background Vitamin C (VitC) is a cofactor for TET enzymes involved in DNA demethylation and epigenetic regulation. Mutations in TET2 are common drivers of leukemia. Preclinical studies suggest that VitC may delay leukemia progression. This study aimed to evaluate the biological activity, safety, and clinical impact of oral VitC in patients ...
Stine Ulrik Mikkelsen, Ali Al‐Mousawi, Amalie Bach Puglisi, Anders Pommer Vallentin, Astrid Østergaard Mortensen, Zachary Madaj, Toshinori Hinoue, Heidi Naomi Ottesen, Jakob Schmidt Jespersen, Linn Gillberg, Morten Tulstrup, Niels Richard Hansen, Jakob Werner Hansen, Mette Klarskov Andersen, Stacey Lyn Thomas, Christine Isaguirre, Ryan Sheldon, Marie Adams, Ryan Burgos, Stephen Baylin, Bo Kok Mortensen, Casey Lee O’Connell, Marianne Tang Severinsen, Peter William Laird, Jens Lykkesfeldt, Peter Jones, Kirsten Grønbæk   +26 more
wiley   +1 more source

<i>TP53</i> mutation analysis in myelodysplastic syndromes - long or short read sequencing? [PDF]

Haematologica
Mittelman M, Shlush L.
europepmc   +1 more source

Outcomes of adult patients with Li‐Fraumeni syndrome and myeloid neoplasms

Cancer, Volume 132, Issue 19, 1 October 2026.
Abstract Background Li‐Fraumeni syndrome (LFS) is an inherited cancer predisposition syndrome. Hematologic malignancies are not considered LFS defining tumors, however, both acute lymphoblastic leukemia and therapy‐related myeloid neoplasms (MNs) in LFS are described. Treatment approaches and outcomes of MN in LFS need further evaluation.
Jayastu Senapati, Hiam M. Abdel‐Salam, Vladislav D. Jdanov, Sanam Loghavi, Ashley Woodson, Jessica Corredor, Gautam Borthakur, Naval G. Daver, Tapan M. Kadia, Koichi Takahashi, Yesid Alvarado, Naveen Pemmaraju, Uday R. Popat, Elizabeth J. Shpall, Farhad Ravandi, Florencia McAllister, Najat C. Daw, Guillermo Garcia‐Manero, Banu K. Arun, Courtney D. DiNardo   +19 more
wiley   +1 more source